Clinical trials: Hydroxychloroquine
COVID-19
Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19
This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating outpatients with suspected or confirmed COVID-19.
- Trial name
- HyAzOUT (NCT04334382)
- Testing
- Hydroxychloroquine, Azithromycin
- Where
- 2 sites in United States
- Volunteers
- 1,550 people
- Sponsor
- Intermountain Health Care, Inc.
Retinitis Pigmentosa
Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)
This research study is being done to learn what effect 12 months of treatment with oral hydroxychloroquine (HCQ) will have on the retina in people with retinitis pigmentosa (RP).
- Trial name
- NCT04120883
- Testing
- Hydroxychloroquine lower dose, Hydroxychloroquine higher dose
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Michigan
Coronavirus Infection
Hydroxychloroquine in Outpatient Adults With COVID-19
Primary Objective: To assess the effect of hydroxychloroquine versus placebo on nasopharyngeal SARS-CoV-2 viral load in outpatient adults with COVID-19 Secondary Objectives: To assess the effect of hydroxychloroquine versus…
- Trial name
- NCT04333654
- Testing
- Hydroxychloroquine SAR321068
- Where
- 7 sites in United States, Belgium and 2 more
- Volunteers
- 8 people
- Sponsor
- Sanofi
Metastatic Clear Cell Renal Cell Carcinoma
Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma
This is an open labeled phase I dose escalation study of hydroxychloroquine (HCQ) and RAD001 in patients with advanced renal cell carcinoma followed by a Phase II trial of RAD001 with HCQ.
- Trial name
- NCT01510119
- Testing
- Hydroxychloroquine, RAD001
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Inflammatory Cardiomyopathy, Myocarditis
The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy
Evaluating the long-term therapeutic effects and safety of hydroxychloroquine(compared to glucocorticoid therapy alone) in patients with inflammatory cardiomyopathy--a multicenter randomized controlled study
- Trial name
- HYPIC (NCT05961202)
- Testing
- Hydroxychloroquine, Prednisolone
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tongji Hospital
Autoimmune Diseases, Sjogren's Syndrome
Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome
Primary Sjögren syndrome is one of the most prevalent autoimmune diseases that present with dry eye and dry mouth. But there is no proven effective treatment for Sjögren syndrome patient.
- Conditions
- Autoimmune Diseases, Sjogren's Syndrome, Dry Eye
- Trial name
- NCT01601028
- Testing
- Hydroxychloroquine
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Seoul National University Hospital
Systemic Lupus Erythematosus (SLE)
3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol
The natural history of Systemic lupus erythematosus (SLE) is characterized by relapses or flares alternated with periods of remission.
- Trial name
- 3TR-SLE1 (NCT05458622)
- Testing
- Blood sample, Urine sample, Saliva sample
- Where
- France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Brest
Systemic Lupus Erythematosus, SLE
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
This trial seeks to describe the effect of withdrawal from mycophenolate mofetil (MMF) on risk of clinically significant disease reactivation in quiescent SLE patients who have been on long-term MMF therapy.
- Trial name
- ALE06 (NCT01946880)
- Testing
- Mycophenolate Mofetil, Hydroxychloroquine or Chloroquine, Prednisone
- Where
- 19 sites in United States
- Volunteers
- 102 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers
Phase 1 randomized, vehicle-controlled, blinded study to assess the safety, tolerability, and PK of single ascending doses of inhaled TLC19 in healthy volunteer subjects.
- Trial name
- NCT04697654
- Testing
- TLC19, TLC19 Vehicle
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Taiwan Liposome Company
COVID-19, End Stage Renal Disease
The Danish Pre-HCQ COVID Dialysis Study
Hydroxychloroquine has been shown to inhibit replication of SARS-CoV-2 in vitro. The presented multicenter parallel-group open-label randomized clinical trial aims to investigate the efficacy of prophylactic hydroxychloroquine on…
- Trial name
- NCT05110651
- Testing
- Hydroxychloroquine
- Where
- 3 sites in Denmark
- Sponsor
- Nicholas Carlson
Hydroxychloroquine Retinopathy
Novel ERG for Detection of Hydroxychloroquine Retinopathy
The purpose of the study is to investigate novel electroretinography (ERG) devices in the detection of hydroxychloroquine retinopathy.
- Trial name
- NCT06035887
- Testing
- Hand-Held Full-Field Skin-Electrode Electroretinography (Device to be evaluated), Trolley-Mounted Multifocal Skin-Electrode Electroretinography (Device to be evaluated), Spectral-Domain Optical Coherence Tomography (Standard of Care test)
- Where
- United Kingdom
- Volunteers
- 140 people
- Sponsor
- King's College Hospital NHS Trust
Covid19, Pneumonia
Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.
Comparison outcomes of a large cohort of moderate and severe COVID-19 patients received different Antiviral and Anti Inflammatory Drugs.
- Trial name
- NCT04779047
- Testing
- Remdesivir, Hydroxychloroquine, Tocilizumab
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- October 6 University
Covid-19, Corona Virus Infection
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19
Introduction There are currently no treatments with demonstrated efficacy for COVID-19 infection. Epidemiological evidence points to the existence of intrinsic protection factors which make young persons and women more resistant…
- Conditions
- Covid-19, Corona Virus Infection, SARS-CoV 2
- Trial name
- OsCOVID19 (NCT04386447)
- Testing
- Oxytocin, Standard of Care
- Where
- 3 sites in France, Italy
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Complication
Prevention of Complications (SARS-CoV-2): Clinical Study
Viral diseases have always posed a threat to public health. Recently, the SARS-Cov2 virus spread in an epidemic that began in China and soon spread globally, making its study extremely relevant, in order to seek mechanisms to…
- Trial name
- NCT04788355
- Testing
- Control group (standard hospital treatment), Group Hydroxychloroquine, Group Hydroxychloroquine and apixaban
- Where
- Brazil
- Volunteers
- 176 people
- Sponsor
- Universidade do Vale do Sapucai
Immune Thrombocytopenia, Systemic Lupus Erythematosus
Retrospective Analysis of the Safety and Efficacy of Hydroxychloroquine in Immune Thrombocytopenia
Retrospective study of the safety and efficacy of hydroxychloroquine among patients with immune Thrombopenia (ITP).
- Trial name
- HCQITP (NCT01549184)
- Volunteers
- 40 people
- Sponsor
- Henri Mondor University Hospital
Solid Tumor
HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors
Baseline levels of PAR-4 secreted by normal cells are generally inadequate to cause massive apoptosis in cancer cells and drugs that bolster the secretion of PAR-4 would constitute an important therapeutic advance.The apoptosis…
- Trial name
- NCT02232243
- Testing
- Hydroxychloroquine, 200mg twice dailiy, Hydroxychloroquine, 400mg twice daily
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Peng Wang, MD PhD
Malignant Solid Tumour
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
This study is an open label non randomized study of hydroxychloroquine (HCQ) with histone deacetylase (HDAC) inhibitor Vorinostat in patients with advanced solid tumors to determine the maximum tolerated dose (MTD) and to…
- Trial name
- NCT01023737
- Testing
- Hydroxychloroquine, Vorinostat
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
COVID-19
Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)
COVID-19 is a respiratory disease caused by the new coronavirus (SARS-CoV-2) and causes considerable morbidity and mortality. Currently, there is no vaccine or therapeutic agent to prevent and treat a SARS-CoV-2 infection.
- Trial name
- TOCOVID (NCT04332094)
- Testing
- Tocilizumab, Hydroxychloroquine, Azithromycin
- Where
- 7 sites in Spain
- Volunteers
- 276 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Lichen Planus, Oral
Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus
This study will compare two treatments for oral lichen planus - hydroxychloroquine (Plaquenil) tablets and clobetasol oral rinse.
- Trial name
- NCT00102557
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Individuals Undergoing Cardiac and General Surgery
Hydroxychloroquine and Cognitive Function After Surgery
The purpose of this study is to determine whether hydroxychloroquine decreases the relative leakage of the brain barrier after surgery.
- Trial name
- NCT03025087
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University